Advertisement
U.S. markets open in 2 hours 14 minutes
  • S&P Futures

    5,068.25
    -12.75 (-0.25%)
     
  • Dow Futures

    38,875.00
    -118.00 (-0.30%)
     
  • Nasdaq Futures

    17,877.25
    -38.00 (-0.21%)
     
  • Russell 2000 Futures

    2,048.30
    +4.90 (+0.24%)
     
  • Crude Oil

    78.44
    -0.10 (-0.13%)
     
  • Gold

    2,038.00
    -4.70 (-0.23%)
     
  • Silver

    22.56
    -0.08 (-0.36%)
     
  • EUR/USD

    1.0833
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    14.01
    +0.17 (+1.23%)
     
  • GBP/USD

    1.2649
    -0.0011 (-0.08%)
     
  • USD/JPY

    149.9720
    -0.6610 (-0.44%)
     
  • Bitcoin USD

    62,543.77
    +3,338.09 (+5.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,650.53
    +25.55 (+0.34%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

Johnson & Johnson JNJ announced that it submitted a supplemental biologics license application (sBLA) seeking approval for the expanded use of its cancer drug, Rybrevant (amivantamab-vmjw).

The sBLA seeks Rybrevant's approval in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) for patients whose disease has progressed on or after treatment with AstraZeneca’s Tagrisso (osimertinib).

The sBLA was based on data from the phase III MARIPOSA-2 study, which evaluated the safety and efficacy of Rybrevant plus chemotherapy in the given patient population.

Currently, Rybrevant is approved in the United States for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy in the United States. The European Medicines Agency had also granted conditional marketing authorization to Rybrevant for the same indication.

Shares of J&J have plunged 15.1% so far this year against the industry’s growth of 3.8%.

 

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

 

In October 2023, the company presented data from the phase III MARIPOSA-2 study at the European Society for Medical Oncology 2023 Congress.

Data from the same showed that treatment with Rybrevant plus chemotherapy led to a significant improvement in progression-free survival (the primary endpoint) as compared with chemotherapy alone in patients with EGFR-mutated advanced NSCLC following prior osimertinib therapy.

We remind investors that another sBLA is seeking approval for Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertion mutations.

Several other early to mid-stage studies are currently underway, evaluating Rybrevant in NSCLC.

Zacks Rank & Stocks to Consider

J&J currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector are Novo Nordisk A/S NVO, AbbVie Inc. ABBV and Acadia Pharmaceuticals Inc. ACAD, carrying a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, estimates for Novo Nordisk’s 2023 earnings per share have improved from $2.15 to $2.62. During the same period, earnings estimates for 2024 have moved up from $2.46 to $3.07. Year to date, shares of NVO have rallied 52.9%.

Earnings of Novo Nordisk beat estimates in two of the trailing four quarters, met the same once and missed on the other occasion. On average, NVO came up with a four-quarter earnings surprise of 0.58%.

In the past 60 days, estimates for AbbVie’s 2023 earnings per share have improved from $11 to $11.19. During the same period, earnings estimates for 2024 have moved up from $11.05 to $11.14. Year to date, shares of ABBV have lost 14.3%.

Earnings of AbbVie beat estimates in each of the trailing four quarters. On average, ABBV came up with a four-quarter earnings surprise of 2.49%.

In the past 60 days, estimates for Acadia Pharmaceuticals’ 2023 loss per share have narrowed from 41 cents to 34 cents. During the same period, earnings per share estimates for 2024 have moved up from 52 cents to 90 cents. Year to date, shares of ACAD have surged 44%.

Earnings of Acadia Pharmaceuticals beat estimates in two of the trailing four quarters and missed on the other two occasions. On average, ACAD came up with a four-quarter earnings surprise of 20.69%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement